PTC Therapeutics and Eli Lilly to acquire parts of bankrupt Sangamo for up to $264 million
read at Endpoints ↗DealNeutral
The gene-editing company Sangamo Therapeutics has filed for bankruptcy, placing its assets up for sale.
An auction process has identified two bidders: PTC Therapeutics and Eli Lilly, which together will purchase selected business units.
The deal is valued at up to $264 million, reflecting the maximum price the buyers may pay for the acquired assets.
The transaction could reshape the competitive landscape in gene editing as the assets move to larger pharmaceutical players.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction”
read at Endpoints ↗84 words · retrieved Aug 13
comments(0)
5-min edit window · permanent after that